Carbapenemase typing and resistance profile of enteric bacteria isolate with reduced sensitivity to carbapenems in a Lebanese tertiary care center
DOI:
https://doi.org/10.3823/863Keywords:
carbapenems, carbapenemase, bacterial resistance, resistance mechanisms, enterobacteriacae, molecular typingAbstract
Objective: nowadays resistant bacteria represent worldwide a public health problem leading in some cases to a stalemate without any possible treatment. Therefore early detection and identification of carbapenemase producing gram-negative bacteria (GNB) is of crucial importance. Consequently we conducted a study in a tertiary care hospital to analyze the resistance phenotype of the carbapenem resistant GNB (CRGNB).
Methods: we collected all the CRGNB from September 2014 till January 2016, we took randomly 40/126 strains and performed a sensitivity test in addition to a real time multiplex PCR to detect the exact carbapenemase coding genes (bla SPC , bla IMP1, bla VIM , bla NDM , bla KPC , et bla OXA-48). The studied strains were: Escherichia coli (70%), Klebsiella pneumonia (20%), Enterobacter aerogenes (2,5%), Enterobacter cloacae (2.5%) et Klebsiella oxytoca (2.5%).
Results: 100% of the studied strains were intermediate or resistant to ertapenem, 85% intermediate or resistant to imipenem and/or meropenem. 33 / 40 strains (82.5%) are bla OXA-48 positive et one strain (2.5%) is bla NDM positive. the OXA-48 were urinary strains of E coli. 6 / 40 strains (15%) did not express carbapenemase genes in molecular studies.
Conclusion: we note a marked emergence of CPGNB especially bla OXA-48 with high resistance pattern leading to narrow therapeutic options. This requires a rapid detection of such strains of GNB so that to initiate quickly the right preventive and therapeutic measures to avoid hospital epidemics with disastrous consequences.
References
Norrby SR. Carbapenems. Med Clin North Am. 1995 Jul;79(4):745–59.
Queenan AM, Bush K. Carbapenemases: The Versatile β-Lactamases. Clin Microbiol
Rev. 2007 Jul;20(3):440–58.
Meletis G, Oustas E, Bagkeri M. Carbapenemase reports from the Balkans: a
systematic review. Infez Med Riv Period Eziologia Epidemiol Diagn Clin E Ter Delle
Patol Infett. 2014 Jun;22(2):85–106.
Société Française de Microbiologie [Internet]. [cited 2016 Feb 23]. Available from:
http://www.sfm-microbiologie.org
Zahedi Bialvaei A, Samadi Kafil H, Ebrahimzadeh Leylabadlo H, Asgharzadeh M,
Aghazadeh M. Dissemination of carbapenemases producing Gram negative bacteria in
the Middle East. Iran J Microbiol. 2015 Oct;7(5):226–46.
El-Herte RI, Kanj SS, Matar GM, Araj GF. The threat of carbapenem-resistant
Enterobacteriaceae in Lebanon: an update on the regional and local epidemiology. J
Infect Public Health. 2012 Jun;5(3):233–43.
El-Herte RI, Araj GF, Matar GM, Baroud M, Kanafani ZA, Kanj SS. Detection of
carbapenem-resistant Escherichia coli and Klebsiella pneumoniae producing NDM-1 in
Lebanon. J Infect Dev Ctries. 2012 May;6(5):457–61.
Girlich D, Poirel L, Nordmann P. CTX-M expression and selection of ertapenem
resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother.
Feb;53(2):832–4.
Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J.
Meropenem dosing in critically ill patients with sepsis and without renal dysfunction:
intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009 Jul;64(1):142–50.
Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation
to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin
Pharmacol. 2003 Oct;43(10):1116–23.
Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B
against a worldwide collection of Gram-negative pathogens: results from the SENTRY
Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother. 2011
Sep;66(9):2070–4.
Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for
the treatment of multidrug-resistant, including extended-spectrum beta-lactamase
producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010
Jan;10(1):43–50.
Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, et al.
An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase
-producing K. pneumoniae in a Greek University Hospital: molecular characterization,
epidemiology, and outcomes. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010 Feb
;50(3):364–73.
Livermore DM, Mushtaq S, Warner M, Zhang J-C, Maharjan S, Doumith M, et al.
Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant
Enterobacteriaceae isolates. J Antimicrob Chemother. 2011 Jan;66(1):48–53.
Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL.
Higher incidence of acute kidney injury with intravenous colistimethate sodium
compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin
Infect Dis Off Publ Infect Dis Soc Am. 2013 Nov;57(9):1300–3.
Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment Options for Carbapenem-
Resistant Enterobacteriaceae Infections. Open Forum Infect Dis [Internet]. 2015 May 5
[cited 2016 Feb 25];2(2). Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462593/
Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating
infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014 Sep;20(9):862–72
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Alexander Malek, Josselin Abi Chebl, Hadi Younes, Jacques Choucair, Nadim Azar
This work is licensed under a Creative Commons Attribution 4.0 International License.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 3.0 License ©
Copyright policies & self-archiving
This is our Copyright Policy. We are a RoMEO green journal.
| Author's Pre-print: |  author can archive pre-print (ie pre-refereeing) |
| Author's Post-print: | author can archive post-print (ie final draft post-refereeing) |
| Publisher's Version/PDF: | author can archive publisher's version/PDF |
